FridayMay 16, 2025 2:20 pm

TinyGemsBreaks – Capstone Holding Corp. (NASDAQ: CAPS) Reaffirms 2025 Guidance, Highlights M&A Pipeline and Flexible Growth Strategy 

Capstone Holding (NASDAQ: CAPS)  reaffirmed its 2025 targets of a $100 million revenue run-rate and $10 million in adjusted EBITDA, supported by a strong M&A pipeline and disciplined cost control. The company is evaluating acquisition opportunities at 4–6x EBITDA multiples, with up to 45% non-cash consideration, and has secured an equity line of credit to support deals without upfront dilution. Subsidiary Instone remained on track despite seasonal headwinds, with cost run-rate guidance intact and growth expected to pick up in Q3.  To view the full press release, visit https://ibn.fm/kwEhl  About Capstone Holding Corp.  Capstone Holding Corp. (NASDAQ: CAPS) is a…

Continue Reading

FridayMay 16, 2025 11:28 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations…

Continue Reading

FridayMay 16, 2025 9:00 am

TinyGemsBreaks – SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) CEO Highlights Vertical Integration and $184M Asset Base on GotStocks Podcast

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) President and CEO Dr. Richard Lu appeared on the GotStocks Podcast to discuss the company’s vertically integrated model and its $184 million portfolio of revenue-generating clean energy assets. Lu detailed how SolarBank develops, builds, owns, and operates distributed and community solar projects across Canada and the U.S., including partnerships with Honeywell and Qcells. He also highlighted a recent $100 million financing agreement with CIM Group to fund 97 MW of U.S. projects, positioning the company for continued long-term growth. To view the full press release, visit https://ibn.fm/O4yDA About SolarBank…

Continue Reading

ThursdayMay 15, 2025 12:14 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses

Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers.  To view the full press release, visit: https://ibn.fm/TptuC  About Calidi Biotherapeutics  Calidi Biotherapeutics…

Continue Reading

ThursdayMay 15, 2025 11:32 am

TinyGemsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Reports 246% Revenue Growth and Expanding Tour Adoption in Q1 

Newton Golf Company (NASDAQ: NWTG) reported a 246% year-over-year revenue increase to $1.2 million in Q1 2025, driven by surging demand for its Newton Motion and Fast Motion shafts. Gross profit rose to $852,000 with margin expansion to 70%, while net loss narrowed to $0.5 million. More than 30 professionals have adopted Newton shafts, including 8 new players across major tours in Q1. The company also expanded into Japan, added key international distribution, and expects full-year revenue between $6.5 million and $7.0 million.  To view the full press release, visit https://ibn.fm/cK0pp  About Newton Golf  At Newton Golf, we harness the…

Continue Reading

ThursdayMay 15, 2025 11:01 am

TinyGemsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) to Report Q1 2025 Results and Host Investor Webinar Today 

Disseminated on behalf of SolarBank Corporation  SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will release its financial results for the quarter ended March 31, 2025, after market close today, May 15, and will host a webinar at 4:30 p.m. ET to provide a business update and discuss the quarterly performance.  To view the full press release, visit https://ibn.fm/PSk5q  About SolarBank Corporation  SolarBank Corporation is an independent renewable and clean energy project developer and owner focusing on distributed and community solar projects in Canada and the USA. The Company develops solar, Battery Energy Storage System (BESS) and EV Charging projects that sell electricity…

Continue Reading

ThursdayMay 15, 2025 9:00 am

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q1 Revenue of $14.5M, Expands Airtime Business Despite Healthcare Headwinds

NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with $17.7 million in cash and expanded its e-Commerce reach, including a 51% increase in recurring airtime revenue and growing OPKO product sales in China. Management remains focused on high-margin services and strategic healthcare growth. To view…

Continue Reading

WednesdayMay 14, 2025 9:15 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14,…

Continue Reading

TuesdayMay 13, 2025 11:30 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reaches Settlement Agreement with GEM Over Mishawaka Assets

Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced it has executed a settlement agreement with GEM Yield Bahamas Limited and GEM Global Yield LLC SCS, resolving a four-year legal dispute. Under the agreement, GEM has a 55-day due diligence period—subject to extension—to evaluate the transfer of Mullen’s Mishawaka assets in full satisfaction of the judgment. All collection activities will be suspended during this period. Mullen stated it remains focused on expanding its Tunica, Mississippi, manufacturing operations to meet growing demand across its EV product lines.  To view the full press release, visit https://ibn.fm/Aks59  About Mullen Automotive Inc.  Mullen Automotive…

Continue Reading

TuesdayMay 13, 2025 9:20 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval. To view the full press release, visit https://ibn.fm/OENah About…

Continue Reading

Contact us: (512) 354-7000